Acquired Hemophilia A
Conditions
Interventions
None listed
Sponsors
Chugai Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients must satisfy all of the following criteria to be considered eligible for this study. 1)Of the patients assigned the receipt disease name,[acquired coagulation factor deficiency (disease code: D684)], those who are assigned the receipt disease name, [acquired hemophilia A] (confirmed) 2)Patients who were admitted on the date the receipt disease name, [acquired hemophilia A] (confirmed) was assigned 3)Patients with data on administration of an immunosuppressant subsequent to the date of initial admission among admissions with the assigned receipt disease name, [AHA] (confirmed)
Exclusion criteria
Exclusion criteria: Patients for whom any of the following criteria apply will be excluded from this study. The entire observation period will apply for all criteria. 1)Patients assigned the receipt disease name, [antiphospholipid syndrome] (confirmed) 2)Patients assigned the receipt disease name, [lupus anticoagulant] (confirmed) 3)Patients assigned the receipt disease name, [acquired coagulation factor XIII deficiency] (confirmed) 4)Patients assigned the receipt disease name, [autoimmune acquired Von Willebrand's disease] (confirmed) 5)Patients assigned the receipt disease name, [acquired factor V deficiency] (confirmed) 6) Patients assigned the receipt idisease name [primary antiphospholipid antibody syndrome] (confirmed)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following outcome measures will be set. In this study, the outcome measures will be analyzed for overall and each target segment (rehabilitation initiation time, period of immunosuppressant use, hospitalization period, ADL on discharge, hemorrhage, type of infection and Death). 1)Treatment implementation status A)Rehabilitation implementation status Type of rehabilitation, frequency, period up to initiation, duration of continuation 2)Outcome A)ADL on discharge | — |
Secondary
| Measure | Time frame |
|---|---|
| The following outcome measures will be set. In this study, the outcome measures will be analyzed for overall and each target segment (rehabilitation initiation time, period of immunosuppressant use, hospitalization period, ADL on discharge, hemorrhage, type of infection and Death). 1)Epidemiology A)Age/sex B)Comorbidity disease 2)Treatment implementation status A)Use status of hemostatic agents Type of hemostatic agent, initial date of use, period of use B)Use status of immunosuppressants Type of immunosuppressant, amount used, period of use C)Hospitalization period 3) Outcome A)Hemorrhage B)Hospital transfer destination C)Infection D)Thromboembolism E)Death F)Nursing care level G)Dysphagia H)Bedsores I)Criteria for determining the level of independence in daily living for elderly persons with dementia | — |
Countries
Japan
Contacts
Public ContactChugai Pharmaceutical Co., Ltd.
Medical affairs department Medical Science department
Outcome results
None listed